Indication
TYSABRI is indicated as monotherapy for the treatment
of patients with relapsing
forms of multiple sclerosis to delay the accumulation of physical disability and reduce
the frequency of clinical exacerbations. The efficacy of TYSABRI beyond 2 years is unknown. Because TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate multiple sclerosis therapy. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.
TYSABRI is indicated as monotherapy for the treatment
of patients with relapsing
forms of multiple sclerosis to delay the accumulation of physical disability and reduce
the frequency of clinical exacerbations. The efficacy of TYSABRI beyond 2 years is unknown. Because TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate multiple sclerosis therapy. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.
